| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Realized losses, net, on investment securities | - | 0 |
| Net loss | -10,272,178 | -6,843,054 |
| Depreciation | 216,830 | 141,690 |
| Amortization of right-of-use assets | 312,805 | 220,911 |
| Stock-based compensation | 115,895 | 327,174 |
| Shares issued in exchange for services | 99,040 | - |
| Advances, deposits, and other current assets | -129,436 | 26,277 |
| Realization of deferred income tax asset | - | 0 |
| Accounts payable and accrued liabilities | -841,351 | 381,116 |
| Net cash used in operating activities | -10,239,523 | -5,798,440 |
| Proceeds from sale and maturity of investment securities | - | 0 |
| Purchases of property and equipment | 276,983 | 276,983 |
| Purchases of investment securities | - | 0 |
| Net cash (used in) provided by investing activities | -276,983 | -276,983 |
| Proceeds from sale of common stock equity, net of issuance costs | 6,437,251 | 2,963,738 |
| Proceeds from issuance of common stock upon exercise of warrants | 3,467,694 | 1,967,694 |
| Issuance costs for stock dividend | 10,277 | - |
| Net cash provided by financing activities | 9,894,668 | 4,931,432 |
| Net change in cash and cash equivalents | -621,838 | -1,143,991 |
| Cash and cash equivalents at beginning of period | 5,872,767 | - |
| Cash and cash equivalents at end of period | 5,250,929 | - |
Imunon, Inc. (IMNN)
Imunon, Inc. (IMNN)